The biotechnology company has seen a mixed track record when it comes to current year estimate revisions over the past few weeks (2 increases, 1 decrease). The current year loss consensus has narrowed over the past few weeks. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
MacroGenics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.0%.
Some better-ranked stocks in the same sector include Covidien plc (COV), Enzymotec Ltd. (ENZY) and William Demant Holding A/S (WILYY). Covidien and William Demant Holding carry a Zacks Rank #2 (Buy), while Enzymotec holds a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment